INTS INTENSITY THERAPEUTICS, INC.

Nasdaq intensitytherapeutics.com


$ 0.63 $ -0.06 (-8.86 %)    

Monday, 03-Nov-2025 13:05:25 EST
QQQ $ 633.14 $ -2.06 (-0.33 %)
DIA $ 473.81 $ -2.47 (-0.52 %)
SPY $ 684.03 $ -1.59 (-0.23 %)
TLT $ 89.64 $ -0.01 (-0.01 %)
GLD $ 368.34 $ -0.45 (-0.12 %)
$ 0.7302
$ 0.68
$ 0.62 x 100
$ 0.63 x 100
$ 0.57 - $ 0.70
$ 0.19 - $ 3.40
196,619,284
na
34.36M
$ -0.23
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-13-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-14-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 intensity-therapeutics-stock-cools-after-hours-following-395-surge-what-you-should-know

Intensity Therapeutics shares plunged 31.9% after-hours following the publication of Phase 1/2 trial results for its cancer the...

 intensity-therapeutics-reports-early-radiological-and-pathological-results-with-int230-6-demonstrating-high-drug-absorption-tumor-necrosis-and-evidence-of-immune-activation

A pathological complete response ("pCR") has been observed in the first patient evaluated in Cohort A, where each patie...

 benchmark-maintains-speculative-buy-on-intensity-therapeutics-lowers-price-target-to-15

Benchmark analyst Robert Wasserman maintains Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and lowers the pric...

 brookline-capital-upgrades-intensity-therapeutics-to-buy-announces-3-price-target

Brookline Capital analyst Kumaraguru Raja upgrades Intensity Therapeutics (NASDAQ:INTS) from Hold to Buy and announces $3 pr...

 intensity-therapeutics-regains-nasdaq-compliance

Intensity Therapeutics, Inc. (NASDAQ:INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION